FibroBiologics to Present at the DealFlow Discovery Conference
FibroBiologics (Nasdaq: FBLG) announced that Founder and CEO Pete O’Heeron will present at the DealFlow Discovery Conference in Atlantic City on January 28-29, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
FibroBiologics (Nasdaq: FBLG) announced that Founder and CEO Pete O’Heeron will present at the DealFlow Discovery Conference in Atlantic City on January 28-29, 2026. The company presentation is scheduled for 11:30 a.m. ET on January 29, 2026. FibroBiologics is a clinical-stage biotechnology company focused on therapeutics using fibroblasts and fibroblast-derived materials and holds 270+ patents issued and pending. Management will be available for one-on-one investor meetings during the event and provided contact details for further information.
Details
News Market Reaction – FBLG
On Jan 20, the day this news came out, FBLG closed 3.70% below the previous close.
Data tracked by StockTitan Argus for the Jan 20 session.
Key Figures
- Patent portfolio
- 270+ patents issued and pending
- FibroBiologics IP portfolio noted in conference announcement
- Conference dates
- January 28–29, 2026
- DealFlow Discovery Conference timing
- Presentation time
- 11:30 a.m. ET
- Scheduled company presentation on Thursday, January 29
- 52-week range
- $0.2201–$2.12
- Pre-news 52-week low and high for FBLG
Historical Context
-
Detailed 2025 progress, new lab, trials, financings and debt payoff.
-
Announced CEO presentation at BFC Global healthcare investment conference.
-
Reported positive FSdC preclinical results in degenerative disc disease models.
-
Filed Phase 1/2 IND with FDA for CYPS317 in psoriasis.
-
Closed $1.7M registered direct offering with associated warrants.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
clinical-stage medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOUSTON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the DealFlow Discovery Conference taking place January 28-29, 2026, at the Borgata in Atlantic City, New Jersey.
FibroBiologics will deliver a company presentation at 11:30 a.m. ET on Thursday, January 29 and will be available for one-on-one investor meetings throughout the event.
For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.